Zydus Cadila gets USFDA nod to market anti-viral drug Acyclovir

The group now has 95 approvals and has so far filed 249 ANDAs since commencement of the filing process in FY04

Ahmedabad-based pharmaceutical major Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) for marketing anti-viral drug Acyclovir tablets.

“Zydus Cadila has received the final approval from the USFDA to market Acyclovir tablets. The drug falls under the anti-viral segment,” the company said in a statement issued on Wednesday.

The company further said it had received approval for marketing of Acyclovir tablets in the strengths of 400 mg and 800 mg. As per IMS, the estimated sales for Acyclovir tablets in 2014 is $55.8 million.

Earlier this month, the company had received the final approval from the US drug regulator to market Potassium Citrate tablets, which are used in the prevention of kidney stones. The approval to market Potassium Citrate tablets were in strengths of 5,10 and 15 mEq, the company had then said.

The group now has 95 approvals and has so far filed 249 ANDAs since the commencement of the filing process in 2003-04.